Other SGLT2 inhibitors currently in use, include canagliflozin, ipragliflozin, ertugliflozin and empagliflozin, which have multiple functions in the treatment of NAFLD and T2DM by preventing DNL, hepatic inflammation and apoptosis, and increasing fatty acid oxidation (154). The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.